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Brugada syndrome (BrS) is a primary electrical heart disease, which can lead to sudden cardiac death. In older patients with BrS,
the disease may coexist with ischaemic heart disease (IHD) and recent studies support a synergistic proarrhythmic eﬀect of the
two disease entities. We report a case that illustrates this. The index patient was a middle-aged patient with BrS traits, IHD, and
aborted sudden cardiac death. Mutation analysis discovered a novel mutation P468L in the NaV1.5 sodium channel. Surprisingly,
voltage-clamp experiments on the wild-type and mutant NaV1.5 channels expressed in HEK cells revealed no functional eﬀect of
the mutation. In a patient like ours, the distinction between IHD and BrS as the cause of an aborted sudden cardiac death is hard
to establish and mounting evidence shows that coexistence of the two may have a synergistic proarrhythmic eﬀect.
Copyright © 2009 Anders G. Holst et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The Brugada syndrome (BrS) is an inherited primary
electrical heart disease. It is characterized by characteristic
ST segment elevations in the right precordial leads of the
ECG in patients with structurally normal hearts and a high
frequency of malignant ventricular arrhythmias [1]. Patients
withBrSarepredominantlymale,andtheonsetofsymptoms
is usually around the age of 40 years. The disease is believed
to be rather common in South East Asia [2] ,b u ti sr a r ei n
western countries [3]. Arrhythmic events are most common
at rest or during sleep [4]. In 15–20% of BrS patients, the
syndrome is associated with mutations in the SCN5A gene
encoding the cardiac NaV1.5 sodium channel [5–7]. The
inheritance is autosomal dominant with varying penetrance.
In middle aged and elderly patients the phenotype of BrS
and ischaemic heart disease (IHD) may coexists creating a
mixed phenotype and hence possible diagnostic diﬃculties.
Furthermore studies support a synergistic eﬀect between BrS
and IHD in the development of arrhythmic events [8, 9].
Here we describe a patient with BrS traits, IHD, and a novel
missense mutation in the SCN5A gene with an apparently
normal function.
2. Methods
2.1. Molecular-Genetic Analysis. DNA sequencing of the
translated exons with ﬂanking intron sequences of ﬁve genes
encodingKCNQ1,KCNH2,KCNE1,KCNE2,andSCN5Awas
performed [10].
2.2. Functional and Biochemical Analysis of NaV1.5 Channels.













Figure 1: ECG (paper speed 25mm/s) taken just after the patient
was resuscitated. Notice the type-1 BrS conﬁguration in V1 (upper
arrow) and the type 2 conﬁguration in V2 (lower arrow). All
recordings were taken from the same ECG.
or P468L NaV1.5 constructs and 0.2μg of pcDNA3-EGFP.
Human NaV1 . 5i np c D N A 3w a sag i f tf r o mD r .H .A b r i e l
(Lausanne University).
3. Case Presentation
The patient was a 61-year-old Caucasian male with a
history of angina pectoris and four prior elective coronary
angiographies (CAG) in 1996, 1998, 2002, and 2003; all of
these showing atheromatosis but no signiﬁcant stenosis. He
had a long history of cigarette smoking and hypertension.
In December 2006, the patient experienced a syncope
followed by chest pain and was transported to the nearest
emergency department. Upon arrival he developed ventricu-
lar ﬁbrillation, but after two direct current counter shocks
sinus rhythm was restored. An electrocardiogram (ECG)
taken immediately after resuscitation showed (Figure 1(a))
ST segment elevations in lead V1 and V2 with a type-1
BrS conﬁguration in V1. Shortly, hereafter the patient was
transferred from the local community hospital to a regional
hospital to undergo an acute CAG. The CAG demon-
strated a 90% stenosis on the circumﬂex coronary artery,
which was treated with Percutaneous Coronary Intervention
(PCI). TIMI ﬂow both before and after stenting were 3.
Blood samples taken at time of admission showed normal
biochemistry, especially normal troponin T and creatinine
kinases. Transthoracic echocardiography revealed borderline
hypertrophy of the left ventricle but was otherwise normal.
Subsequently the patient underwent an invasive electro-
physiological study (EPS) during which ventricular ﬁbrilla-
tion was induced. Because of the EPS ﬁndings and clinical
signs of BrS in conjunction with an episode of ventricular
ﬁbrillation, the patient received an implantable cardioverter-
deﬁbrillator (ICD). In the two years of follow up, no ICD
therapies, appropriate or inappropriate, had been delivered
(follow up until January 2009).
Years later a ﬂecainide provocation test as well as an
ECG with elevated electrode placement were performed, but
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Figure 2: The family pedigree: the proband (II:1) is marked with
an arrow.
none of these resulted in induction of a type-1BrS ECG
conﬁguration, illustrating the variable nature of the ECG
changes. A retrospective review of the patients ECGs though,
uncovered an ECG from July 2006 showing a BrS Type-1
p a t t e r ni nV 1.
Furthermore,duringtheunravelingofthediseasehistory
it was revealed that many years ago, the patient had
experienced two syncopes.
3.1. Genetic Analysis. The genetic analysis revealed that the
patient was heterozygous for a novel missense mutation
P468L (c.1403C > T) in exon 11 of the SCN5A gene. The
mutation was not identiﬁed in a group of 630 unrelated
subjects referred for genetic testing. The patient did not have
the H558R polymorphism.
3.2. Family History, Clinical Evaluation, and Genetic Testing
of Family Members. The father (I:2) died at age 62 from lung
cancer (Figure 2). The mother (I:1) died suddenly at age 64
butnocauseofdeathwasestablished.Onebrother(II:2)died
at the age of 28, he had a heart valve operation in the years
before his death, but no further information was available.
Another brother (II:3) died at age 59. He had a history of
ischaemic heart disease, but again no cause of death was
known.
The patient had four children, three daughters and
one son, in the age 30–42 years. All daughters carried the
mutation,butnottheson.Nonehavehadanyknowncardiac
diseases or symptoms. The clinical examination revealed an
incomplete right bundle branch block bearing resemblance
to a Type 3BrS conﬁguration in the 42 year old daughter
(III:4) ECG and a ﬂecainide challenge was carried out but
came out negative. ECGs from the last three children were
normal.
3.3. Electrophysiological Characterization of NaV1.5 P468L.
The peak current density did not reveal any diﬀerence
between wild type and P468L mutant channels. To study
the onset of fast inactivation, individual current tracesCase Reports in Medicine 3
Table 1: Kinetic parameters of wild type and P468L current measured in transiently transfected HEK-293 cells.
Wild type P468L
Peak current (at −20mV) −199 ±35pA/pF (n = 11) −213 ±39pA/pF (n = 12)
Steady-state activation, V1/2 −30.4 ±0.6mV(n = 14) −31.8 ±0.6mV(n = 10)
slope, k value 6.2 ± 0.3 mV/e-fold 6.2 ±0.5mV/e-fold
Steady-state inactivation, V1/2 −82.0 ±1.3mV(n = 13) −79.2 ±1.2mV(n = 9)
slope, k value 6.2 ±0.2mV/e-fold 5.9 ±0.3mV/e-fold
were ﬁtted using a biexponential function and the resulting
time constants (τ) were plotted as a function of voltage.
No signiﬁcant diﬀerences in the τfast or τslow values of
mutant channel compared to wild type were found. To
further investigate the phenotype of NaV1.5 P468L, steady-
state activation and inactivation were analyzed, as well as
the voltage- and time-dependent release from inactivation
(Table 1). Again, there was no diﬀerence between wild type
and P468L channels.
4. Discussion
Cardiac enzymes after the cardiac arrest were normal, hence
acute myocardial infarction (AMI) may be excluded, but
transient ischemia cannot. The patients never exhibited
diagnostic ECG changes for BrS, as a type-1 conﬁguration
was only seen in one lead and not the required two. In the
clinical setting the patient was treated as having BrS though.
The patient experienced two syncopes years prior to the
cardiac arrest. The cause of the syncopes could be vasovagal,
but self limiting episodes of ventricular tachycardia cannot
be ruled out.
Genetic screening revealed a novel mutation in SCN5A.
The mutation was found in 3 out of 4 of the progeny, but
none had a BrS phenotype. The mutation not being present
in 630 controls speaks in favor of the P468L substitution
beingtheunderlyingcauseoftheBrStraitsinthepatient,but
the lack of genotype/phenotype cosegregation in the family
weakens the argument. The electrophysiological investiga-
tions of the mutation did not reveal any functional eﬀect
of the P468L substitution, and the substitution could be an
innocent bystander instead of disease causing. However the
mutated sodium channels expressed in HEK-293 cells may
behavediﬀerentlyfrominvivoduetolackofsodiumchannel
interacting proteins, diﬀerent traﬃcking or existence of a
diﬀerent set of polymorphisms.
CoexistenceofBrStraitsandIHDinapatientwithASCD
can pose a problem in the clinical setting since the latter
represents a potentially reversible cause of heart arrest and
the former does not. Future ischemic events can in many
cases be prevented by appropriate interventions whereas
with the diagnosis of BrS and an episode of ASCD an ICD
implantation is mandated [5].
As to the pathogenesis of the ASCD in this patient, the
distinction between IHD and BrS as the substrate of sudden
cardiac death is muddled by a number of reports showing
that BrS increases the risk for arrhythmias during ischemia
[8, 9] although not all studies support this conclusion [11].
The suggested mechanism for this accentuation of the
risk of arrhythmias is the diﬀerence in the ion current
balance (INa/Ito/ICaL) in epicardial versus endocardial cells
of especially the right ventricular outﬂow tract. A balance
that, according to this theory, is disturbed in BrS as well as
during ischemia and the two in combination may have a
synergistic proarrhythmic eﬀect[12]. Furthermore, evidence
is mounting that polymorphisms in SCN5A e x o n sa sw e l la s
in promoter regions has an impact on SCD susceptibility,
albeit not speciﬁcally in the setting of IHD, but one could
speculate that ischemia as well as these genetic changes both
reduce the “antiﬁbrillatory reserve” in a synergistic manner
[13].
Currently many BrS patients are middle aged [14], and
consequently we will in the near future see a large cohort
of BrS patients coming into an age where IHD becomes
prevalent and thus be facing the problems reported in this
study. Further research into the modulating eﬀect of BrS
on the risk of SCD in the setting of IHD is warranted, as
this could potentially lead to changes in risk stratiﬁcation
for BrS patients with high risk of IHD, as well as a better
understanding of the arrhythmia inducing mechanisms
underlying both.
In conclusion, we reported a case of aborted sudden
cardiac death in a patient with coexistence of Brugada
Syndrome traits, ischaemic heart disease, and a novel SCN5A
mutation. The distinction between IHD and BrS as the cause
of an aborted sudden cardiac death is hard to delineate, and
is muddled by mounting evidence showing that coexistence
of the two may have a synergistic proarrhythmic eﬀect.
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